Questions across 84 calls

Tushar Manudhane

Motilal Oswal Financial Services

Laurus Labs Limited

Analysts/Institutional Investor Meet/Con. Call Updates Laurus Labs Limited has informed the Exchange about Transcript · 2023-10-20

So just on the gross margin firstly on sequential basis, when the synth esis business has in fact there has been slight decline and formulation s business has also been quite stable. So , if you could just explain the reason for better gross margin this quarter compared to previous quarter?

Considering the FY24 sales outlook and presumably significant chunk of the business coming from CMO, CDMO side, as you have indicated in just the earlier commentary that the ARV-led API and formula tions could be stable, so does it mean that there should be a significant improvement further in the gross margin in the coming quarters?

Laurus Labs Limited CC-Sep23.pdf · 2023-10-20

So just on the gross margin firstly on sequential basis, when the synth esis business has in fact there has been slight decline and formulation s business has also been quite stable. So , if you could just explain the reason for better gross margin this quarter compared to previous quarter?

Considering the FY24 sales outlook and presumably significant chunk of the business coming from CMO, CDMO side, as you have indicated in just the earlier commentary that the ARV-led API and formula tions could be stable, so does it mean that there should be a significant improvement further in the gross margin in the coming quarters?

Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited CC-Feb26.pdf ·

Thanks for the opportunity. Sir, on the innovative medicine s sales, ex of milestone payment, the growth has been a bit soft compared to the earlier quarters. If you could elaborate on that ? That is my first question.

Secondly, R&D spend on the innovative portfolio both as a percentage of total R&D as well as absolute amount has been reducing for the past two, three quarters. If you could also explain that?

Sun Pharmaceutical Industries Limited CC-Jun24.pdf ·

Sir, just with respect to Ilumya for the indication of psoriatic arthritis, where we are in terms of the recruitment of patients, 60%-70% done, 80%-90% done, if you could share some like that?

Sir, considering that and considering the other product sort of will do completing the Phase- 2 and sort of topline data in first of CY25, so just trying to understand what would lead to big step up in the R&D spend as far as FY25 is concerned?